MYRIAD myRisk®
Hereditary Cancer

Enhanced with a Clinically Validated Precision Medicine Tool

riskScore™
BREAST CANCER

Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

The Fourth Epoch in Hereditary Cancer Testing



riskScore™ BREAST CANCER

The Problem

Myriad Hereditary Cancer Testing Personalized Medicine for WHEN DECISIONS MATTER

Answering the **most** pressing question about cancer

Will I Get Cancer?

myriad WHEN DECISIONS MATTER

Patients Left Without Answers



Despite being at **high familial risk** for development of breast cancer, **fewer than 10%** carry a clinically actionable mutation

riskScore™ BREAST CANCER

CLINICAL UNCERTAINTY

Provider and Patient Left Without a Definitive Answer

0%

12%

Population Risk

Risk of Breast Cancer

87%

BRCA Mutation

100%

riskScore™ BREAST CANCER

Doctors Focus on “Neon Light” Patients Due to Challenge of Negative Test Report

USPSTF Eligible Population



VS

myRisk Family History



Only 10% of Patients Tested Are From the Largest Pool of Patients That Meet Criteria

riskScore™ BREAST CANCER

The Product

riskScore™
BREAST CANCER

riskScore™ is a clinically validated personalized medicine tool that predicts a woman's lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome.

riskScore guides medical management in the prevention of breast cancer morbidity and mortality.

What Does riskScore Measure?

Combines Cutting Edge Science with Best-in-Class Family History Tool

Proprietary score that combines data from >80 single nucleotide polymorphisms (SNPs) with well documented role in predicting cancer risk along with best-in-class family/personal history model (Tyrer-Cuzick model)

Results for unaffected patients with European descent (initially)

Provides residual risk for patients that are negative for myRisk test and is complimentary

riskScore™ BREAST CANCER

Background Information

What is a SNP and Tyrer-Cuzick?

SNP

A single nucleotide polymorphism (SNP) is a variation in a single nucleotide that occurs at a defined point within the genome



Tyrer-Cuzick

Tyrer-Cuzick is a best-in-class family history prediction tool that looks at family history and personal factors such as age, age at first live birth, age at menarche, age at menopause, hormone use, birth control use, and lifestyle choices to assess breast cancer risk



riskScore™ BREAST CANCER

Advancing Genetic Risk Assessment



riskScore™ BREAST CANCER

The Science

Development and Validation of riskScore

Growing Body of Evidence

Researched 20 years of genome wide association data on SNPs in breast cancer risk

Screened > 100,000 patients to select 24,259 patient training study which identified over 80 highly predictive SNPs

10,575 patient validation study showed the SNP panel in riskScore highly predictive of breast cancer risk

Combined genetic markers with family history tool in combined validation in 1,617 patients to be presented at San Antonio Breast Cancer Symposium

riskScore™ BREAST CANCER

riskScore Data Shows Test Highly Impactful & Accurate

Risk Distribution From Combined Risk Score



SNP panel was highly statistically significant for lifetime and breast cancer risk with a p-value of 10^{-31}

Combined risk score with SNP panel and Tyrer-Cuzick was highly statistically significant for both lifetime and five-year breast cancer risk with a p-value of 10^{-34} and 10^{-38} respectively

Patients have a broad distribution of relative risk with many significantly above and below the population risk

riskScore™ BREAST CANCER

The Report

Patient #1

CONFIDENTIAL

myRisk Genetic Result

Name: **Case Study 1** DOB: **Feb 20, 1977** Accession #: **00000000-000** Report Date: **Sept 4, 2017**

Breast Cancer riskScore™

riskScore™ BREAST CANCER

Breast Cancer riskScore™

15.2%

RESULT: 15.2% Remaining Lifetime Risk for Breast Cancer
0.7% 5-Year Risk for Breast Cancer

Breast Cancer riskScore™ - Remaining Lifetime Risk



BREAST CANCER RISKSCORE™ INTERPRETATION

The breast cancer riskScore™ provides an estimate of the remaining lifetime risk for breast cancer. A risk estimate greater than 20% is associated with specific modified medical recommendations, including consideration of more aggressive breast cancer screening and additional risk reduction measures. If applicable, details of these recommendations are provided in the accompanying myRisk Medical Management Tool or other supplemental material. Women with a risk estimate below 20% may still be appropriate for consideration of modified medical management based on other clinical factors or estimates from other breast cancer risk models, such as Tyrer-Cuzick, Claus, and Gail.

BREAST CANCER RISKSCORE™ ANALYSIS DESCRIPTION

The breast cancer riskScore™ provides 5-year and remaining lifetime breast cancer risks, based on an analysis of genetic markers combined with patient clinical and family history data. The Technical Specifications summary (https://www.myriadpro.com/documents-and-forms/technical-specifications/) describes the analysis, method, performance and interpretive criteria of this test. In some cases, due to biological or technical limitations, analyses of all ___ biomarkers may not be performed. It is unlikely that data from the un-analyzed markers would have a large impact on breast cancer risk estimates provided. ___/86 markers were analyzed for this patient. Clinical and family history data used for this analysis is shown in the Clinical and Cancer Family History Information section of this report. The accuracy of this information can significantly affect the provided breast cancer risk estimates.

Please contact Myriad Medical Services at 1-800-469-7423 X 3850 to discuss any questions regarding this result.

This **Authorized Signature** pertains to this laboratory report:

Benjamin B. Roa, PhD
Diplomate ABMG
Laboratory Director

Richard J. Wenstrup, MD
Diplomate ABMG
Chief Medical Officer

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. The patient's clinical history and test results should not be disclosed to a third party, unless related to treatment or payment for treatment, without the patient's express written authorization. It is strongly recommended that these results be communicated to the patient in a setting that includes appropriate counseling. This test was developed and its performance characteristics determined by Myriad Genetic Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that clearance or approval for laboratory-developed tests is not required.

myriad.

Patient #2

CONFIDENTIAL

myRisk Genetic Result

Name: **Case Study 3** DOB: **Feb 25, 1980** Accession #: **00000000-000** Report Date: **Sept 4, 2017**

Breast Cancer riskScore™

riskScore™ BREAST CANCER

Breast Cancer riskScore™

33.7%

RESULT: 33.7% Remaining Lifetime Risk for Breast Cancer
1.7% 5-Year Risk for Breast Cancer

Breast Cancer riskScore™ - Remaining Lifetime Risk

BREAST CANCER RISKSCORE™ INTERPRETATION

The breast cancer riskScore™ provides an estimate of the remaining lifetime risk for breast cancer. A risk estimate greater than 20% is associated with specific modified medical recommendations, including consideration of more aggressive breast cancer screening and additional risk reduction measures. If applicable, details of these recommendations are provided in the accompanying myRisk Medical Management Tool or other supplemental material. Women with a risk estimate below 20% may still be appropriate for consideration of modified medical management based on other clinical factors or estimates from other breast cancer risk models, such as Tyrer-Cuzick, Claus, and Gail.

BREAST CANCER RISKSCORE™ ANALYSIS DESCRIPTION

The breast cancer riskScore™ provides 5-year and remaining lifetime breast cancer risks, based on an analysis of genetic markers combined with patient clinical and family history data. The Technical Specifications summary (https://www.myriadpro.com/documents-and-forms/technical-specifications/) describes the analysis, method, performance and interpretive criteria of this test. In some cases, due to biological or technical limitations, analyses of all ___ biomarkers may not be performed. It is unlikely that data from the un-analyzed markers would have a large impact on breast cancer risk estimates provided. ___/86 markers were analyzed for this patient. Clinical and family history data used for this analysis is shown in the Clinical and Cancer Family History Information section of this report. The accuracy of this information can significantly affect the provided breast cancer risk estimates.

Please contact Myriad Medical Services at 1-800-469-7423 X 3850 to discuss any questions regarding this result.

This **Authorized Signature** pertains to this laboratory report:

Benjamin B. Roa, PhD
Diplomate ABMG
Laboratory Director

Richard J. Wenstrup, MD
Diplomate ABMG
Chief Medical Officer

These test results should only be used in conjunction with the patient's clinical history and any previous analysis of appropriate family members. The patient's clinical history and test results should not be disclosed to a third party, unless related to treatment or payment for treatment, without the patient's express written authorization. It is strongly recommended that these results be communicated to the patient in a setting that includes appropriate counseling. This test was developed and its performance characteristics determined by Myriad Genetic Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that clearance or approval for laboratory-developed tests is not required.

myriad.

riskScore™ BREAST CANCER

riskScore Example Report



Provides individual risk score for breast cancer based upon genetic markers and Tyrer-Cuzick

riskScore™ BREAST CANCER

Breast Cancer Screening Guidelines

The National Comprehensive Cancer Network and the American Cancer Society recommended annual breast MRI, in addition to mammogram, for women with >20% lifetime risk of breast cancer

Advancing the Science with Actionable Results

Uncertainty

GENETIC TEST RESULT: **NEGATIVE**

MEDICAL MANAGEMENT:

- Clinical Breast Exam and Breast Awareness

Myriad myRisk®

GENETIC TEST RESULT: **NEGATIVE**

RISKSCORE: **33.7%**

MEDICAL MANAGEMENT:

- Clinical Breast Exam and Breast Awareness
- Mammography
- MRI
- Risk Reducing Strategies

riskScore™ BREAST CANCER

The Opportunity

Market Research Shows High Interest Level in riskScore

Would you change medical management based upon the combined score?



How would this enhancement impact the competitive advantage of myRisk relative to other panel tests?



Physicians Believe riskScore Provides Incremental Value

“If it gets marketed to the vast public, then I think Myriad will have a test that nobody else has.”

“riskScore adds another piece of the puzzle. The sum of all information adds to an increased risk.“

"This is the most valuable thing a sales rep has shown me in years."

91% 87%

“Myriad should be commended for the development of riskScore and advancing the science as it relates to refinement of breast cancer risk.”

Provides Reason for Preventive Care Doctors To Go “Deeper”



- From the “trusted advisor” in hereditary cancer
- Given low positive rate, average preventive care physician only looks for “neon light” patients
- **EVERY** patient will now have an individualized assessment of breast cancer risk
- Improved test value can drive deeper penetration
- Expands an already significant competitive moat

Myriad Will Continue to Be a Scientific Pioneer

- Commercially available as of today
- SNP Panel validation to be presented at National Society of Genetic Counselors annual meeting
- Combined validation (SNP Panel + Tyrer-Cuzick) presented at San Antonio Breast Cancer Symposium in December
- Work ongoing to identify breast cancer SNPs for additional ethnicities
- Future work will expand into other cancers